Windham Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Windham Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,301	Closed	-$2.08M	–	52
2023 Q4	$2.08M	Buy	15,301 +33	+0.2%	+$4.03K	0.77%	36
2023 Q3	$1.87M	Hold	15,268	–	–	0.75%	36
2023 Q2	$1.94M	Hold	15,268	–	–	0.75%	37
2023 Q1	$1.97M	Buy	15,268 +568	+4%	+$74.4K	0.78%	37
2022 Q4	$1.93M	Hold	14,700	–	–	0.74%	33
2022 Q3	$1.72M	Hold	14,700	–	–	0.65%	36
2022 Q2	$1.73M	Hold	14,700	–	–	0.41%	36
2022 Q1	$1.92M	Hold	14,700	–	–	0.41%	36
2021 Q4	$2.24M	Hold	14,700	–	–	0.46%	34
2021 Q3	$2.38M	Hold	14,700	–	–	0.5%	31
2021 Q2	$2.41M	Hold	14,700	–	–	0.49%	30
2021 Q1	$2.21M	Hold	14,700	–	–	0.47%	31
2020 Q4	$2.23M	Hold	14,700	–	–	0.48%	28
2020 Q3	$1.99M	Hold	14,700	–	–	0.44%	28
2020 Q2	$2.01M	Hold	14,700	–	–	0.46%	26
2020 Q1	$1.58M	Hold	14,700	–	–	0.38%	28
2019 Q4	$1.77M	Hold	14,700	–	–	0.38%	38
2019 Q3	$1.46M	Hold	14,700	–	–	0.33%	34
2019 Q2	$1.6M	Hold	14,700	–	–	0.27%	30
2019 Q1	$1.64M	Buy	+14,700	New	+$1.61M	0.28%	30

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Windham Capital Management's IBB Position: Q1 2024 in Review

Windham Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2024, closing a stake of 15,301 shares — an estimated $2.08M sold.

Windham Capital Management first reported a position in IBB in Q1 2019 and held it in 20 quarters. The position peaked at $2.41M in Q2 2021. 900 funds tracked by Wall St. Rank hold IBB as of Q1 2024.

Windham Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2024 after selling out during the quarter.
Windham Capital Management sold 15,301 iShares Biotechnology ETF shares in Q1 2024, an estimated $2.08M.
Windham Capital Management first reported a position in iShares Biotechnology ETF in Q1 2019 and held it in 20 quarters.
Windham Capital Management's iShares Biotechnology ETF position peaked at $2.41M in Q2 2021.
900 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2024.

Based on Windham Capital Management's 13F filing for Q1 2024, filed 13 May 2024.